According to incomplete statistics from Innovation Radar, last week (July 21 to July 27)Global Health Sector Discloses 22 Financing Events, Totaling Over $1.1 Billion, covering financing at multiple stages from early to IPO. Financing in China is concentrated in the fields of innovative drugs and medical devices, with prominent financing in regions such as Jiangsu and Shanghai; innovative drugs in the United States attract substantial investment. In terms of industry distribution, small nucleic acids, antibody drugs, and small molecule inhibitors have become investment hotspots.

Compared with the previous weeks, the primary market financing in the global innovative drug sector rebounded slightly last week, with an increase in large-scale financings exceeding 100 million US dollars.

Among them,Dispatch Bio Raises $216 Million in Series A Financing, Becoming the Potential Highest Single-Round Funding ProjectThe company's technology platform provides an innovative solution for solid tumor treatment by precisely labeling tumor cells and remodeling the tumor microenvironment. This round of financing will advance the development of its candidate drugs, with the first project expected to enter clinical trials in 2026.

In addition,Avalyn Pharma Completes $100 Million Series D Financing Round with Investments from Multiple Renowned Institutions, which will be used to advance key clinical milestones in the field of pulmonary fibrosis treatment, including late-stage clinical studies of core pipelines AP01 and AP02, as well as the clinical development of combination therapy AP03.

IPO Market,Vivavision Listed on HKEX, Raising Approximately US$189 Million. This is also the second innovative drug company to be listed on the Hong Kong Stock Exchange this month after Dispatch Bio. VivaVision focuses on three major areas: Tumor Immunotherapy 2.0, T-cell engagers (TCE), and antibody-drug conjugates (ADC). Currently, its oncology pipeline includes a total of 12 products targeting various cancers such as non-small cell lung cancer, hepatocellular carcinoma, and multiple myeloma. These include three monoclonal antibodies, five bispecific antibodies, three ADCs, and one bispecific fusion protein. Additionally, in the field of autoimmune diseases, VivaVision has developed one bispecific fusion protein and one trispecific antibody.

Two financing events occurred in the nucleic acid field.Ribo Life Science Secures Over 200 Million Yuan in E-Round Funding, with Cumulative Multi-Round Financing Exceeding 1.8 Billion Yuan.This round of funding will advance the development of self-developed clinical pipelines in cardiovascular, metabolic, renal, and liver diseases, as well as enhance innovation in the extrahepatic delivery technology platform. The company has established a small nucleic acid drug R&D platform, where its liver-targeted delivery technology has propelled multiple products into Phase 2 clinical trials.

NEWISH Completes Tens of Millions of Yuan in B1 FinancingThe company focuses on the field of early cancer treatment. Its STARi nucleic acid drug development platform adopts a strategy of enhancing T-cell immunity by linking chemokines, aiming to develop novel cancer vaccines. Currently, it has established pipelines for HPV infection-related diseases and liver cancer.

In addition to continuous breakthroughs in the small nucleic acid field, the development of new ophthalmic drugs has also attracted capital attention.VIVAVISION Completed Over 100 Million Yuan in D2+ Round Financing Last WeekThe core pipeline includes VVN001 eye drops for dry eye syndrome, which is in Phase 3 clinical trials; the first patient has been successfully enrolled in the Phase 2 trial for VVN1901 in the treatment of neurotrophic keratitis.

In the field of medical devices,BrioHealth Solutions Completes Over USD Strategic Financing Round with Participation from Gaorong Capital, Sequoia China and OthersThe company is committed to the research and development of implantable ventricular assist devices, and its product BrioVAD has been approved by the U.S. FDA for clinical trials.

Readers, please star ⭐Chuangjianhui to receive push notifications in the first place.

Disclaimer: This article is for information exchange purposes only. The views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: Welcome to share to Moments. Unauthorized media or institutions are prohibited from reprinting or copying in any form to other platforms. For reprint authorization, please contact"Chuangjian Hui"Contact us by leaving a message on our WeChat Official Account.

More Data Content Recommended

Click "InSee", Share Chuangjian Hui Health New Dynamics